Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Zajicek

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Lancet (London, England)|November 15, 2003
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trialJohn Zajicek, Patrick Fox, Hilary Sanders, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 21, 2012
Putting the Alzheimer's cognitive test to the test I: traditional psychometric methodsJeremy Hobart, Stefan Cano, Holly Posner, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 21, 2012
Putting the Alzheimer's cognitive test to the test II: Rasch Measurement TheoryJeremy Hobart, Stefan Cano, Holly Posner, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 12, 2013
Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosisJeremy Hobart, Stefan Cano, Rachel Baron, et al.
Acta Neuropathologica|November 19, 2013
Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's diseaseDavid Hilton, Madeleine Stephens, Leanne Kirk, et al.
The Lancet. Neurology|July 15, 2019
Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysisJennifer Freeman, Wendy Hendrie, Louise Jarrett, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 9, 2013
Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approachHolly B Posner, Stefan Cano, Maria C Carrillo, et al.
The Lancet. Neurology|July 17, 2013
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trialJohn Zajicek, Susan Ball, David Wright, et al.
BJGP Open|December 20, 2018
Machine-learning based identification of undiagnosed dementia in primary care: a feasibility studyEmmanuel A Jammeh, Camille B Carroll, Stephen W Pearson, et al.
JAMA Neurology|October 31, 2022
Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical TrialKara N Stevens, Siobhan Creanor, Alison Jeffery, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Lancet (London, England)|November 15, 2003
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trialJohn Zajicek, Patrick Fox, Hilary Sanders, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 21, 2012
Putting the Alzheimer's cognitive test to the test I: traditional psychometric methodsJeremy Hobart, Stefan Cano, Holly Posner, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 21, 2012
Putting the Alzheimer's cognitive test to the test II: Rasch Measurement TheoryJeremy Hobart, Stefan Cano, Holly Posner, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 12, 2013
Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosisJeremy Hobart, Stefan Cano, Rachel Baron, et al.
Acta Neuropathologica|November 19, 2013
Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's diseaseDavid Hilton, Madeleine Stephens, Leanne Kirk, et al.
The Lancet. Neurology|July 15, 2019
Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysisJennifer Freeman, Wendy Hendrie, Louise Jarrett, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 9, 2013
Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approachHolly B Posner, Stefan Cano, Maria C Carrillo, et al.
The Lancet. Neurology|July 17, 2013
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trialJohn Zajicek, Susan Ball, David Wright, et al.
BJGP Open|December 20, 2018
Machine-learning based identification of undiagnosed dementia in primary care: a feasibility studyEmmanuel A Jammeh, Camille B Carroll, Stephen W Pearson, et al.
JAMA Neurology|October 31, 2022
Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical TrialKara N Stevens, Siobhan Creanor, Alison Jeffery, et al.
Pageof 3